Noubar Afeyan, Director at Moderna, Inc. (MRNA), sold 25,400 shares at $116.01 ($3.0M) on 2024-07-10, disclosed to the SEC on 2024-07-12.
Scheduled sale ($3.0M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $116.01 | 6,121 | $710K | 23.9% |
| 2 | $116.01 | 6,121 | $710K | 23.9% |
| 3 | $117.18 | 4,279 | $501K | 16.9% |
| 4 | $117.18 | 4,279 | $501K | 16.9% |
| 5 | $117.83 | 3,000 | $353K | 11.9% |
| 6 | $119.28 | 1,100 |
| $131K |
| 4.4% |
| 7 | $119.95 | 500 | $60K | 2.0% |
| Total | $116.84 avg | 25,400 | $3.0M | 100% |
| Filing → |
| MRNA | SELL | 2025-12-15 | $1.4M | — | Filing → |
| MRNA | SELL | 2024-08-02 | $3.6M | — | Filing → |
| MRNA | SELL | 2024-07-26 | $2.9M | — | Filing → |